CytoDyn (OTCQB:CYDY -32.3%) is under pressure on more than a 6x surge in volume on the heels of a critical report from short seller Citron Research who regards the stock as a “big joke” about its claim to have developed a cure for COVID-19 with “zero” data related to over-hyped leronlimab.
Before today’s action, the stock had rallied 186% since June 17.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.